前立腺癌に対する女性ホルモン剤投与による血清過酸化脂質ならびにHDL-コレステロールの変化について

Abstract

We measured serum lipid peroxide (LPO) and HDL-cholesterol levels in patients with prostatic cancer before and during the course of anti-androgenic treatment. The patients under the anti-androgen treatment showed significantly higher serum LPO and HDL-cholesterol levels than those of non-treated patients. The patients who suffered from cardiovascular disease during the anti-androgen treatment sumed to be classified into two groups in terms of serum LPO, triglyceride (TG) and HDL-cholesterol levels. In one group, remarkable elevation of serum TG and LPO levels was observed after the initiation of anti-androgen administration, while serum HDL-cholesterol levels were raised only slightly. In another group, anti-androgen administration caused remarkable elevation of serum HDL-cholesterol levels, but evident change of serum TG and LPO levels. In some of the anti-androgen treated patients, rivoflavin tetrabutyrate was administered to prevent these anti-androgen induced abnormalities of serum lipids levels. The elevated serum TG and LPO levels were lowered, and simultaneously serum FFA levels were raised. No remarkable change was observed on serum HDL-cholesterol levels. It is tempting to assume that anti-androgenic agents may have suppressed TG-lipase activity and it may be recovered by the administration of rivoflavin tetrabutyrate.